World · India Bureau
Sun Pharma Holds Investor Appeal Despite Mixed Q2 Performance
Market analysts maintain a positive outlook on Sun Pharmaceutical Industries despite a slowdown in US and specialty drug segments during the second quarter of FY27. Strong domestic business performance is underpinning confidence, even as near-term profit forecasts face downward revision.
LSN India ·
Sun Pharmaceutical Industries has retained analyst backing despite reporting mixed results in the second quarter of FY27, with weakness in key international markets offset by resilience in its Indian operations. The pharmaceutical major saw slower growth in its US business and specialty segments during the period, raising near-term profitability concerns among market watchers.
Several brokerages have trimmed their earnings estimates for the company in light of the subdued performance in high-value markets. However, the consensus view remains constructive, with analysts pointing to robust domestic sales as a stabilizing factor for the company's overall financial trajectory.
The strength of Sun Pharma's Indian business, traditionally a significant revenue contributor, continues to provide confidence to investors navigating concerns about international market headwinds. Analysts suggest that sustained domestic momentum could help the company absorb near-term pressures and support medium-term growth prospects.
The downward revision of earnings forecasts reflects a more cautious near-term outlook, though market sentiment indicates belief in the company's underlying business fundamentals. Sun Pharma's diverse portfolio and established market position in India's pharmaceutical sector remain factors supporting investor interest despite the current quarter's challenges.